ThriVent: Flow Rate Impact on Arterial Carbon Dioxide During THRIVE

Sponsor
Uppsala University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05234424
Collaborator
(none)
18
1
2
8
2.2

Study Details

Study Description

Brief Summary

Apneic oxygenation describes the process of continuous oxygenation of the blood without breathing efforts. This anesthesia technique has been described in the literature for more than 100 years and is sometimes used under general anesthesia, e.g. during surgery of the vocal chords. Although this technique usually provides marked prolongation of the apneic period because of excellent oxygenation, it is limited by the absence of ventilation and the corresponding accumulation of carbon dioxide in the blood. This will lead to worsening respiratory acidosis and associated complications, such as cardiac arrythmias.

In 2015 it was reported that apneic oxygenation with high-flow nasal oxygen delivery systems (HFNO), a device that provides heated humidified oxygen at high flow rates (usually 30-70 L/min), resulted in less carbon dioxide accumulation compared with historical controls. This specific technique of apneic oxygenation was termed transnasal humidified rapid-insufflation ventilation exchange (THRIVE). To date, the impact on different flow rates on blood carbon dioxide accumulation during THRIVE is unknown. Specifically, very high flow rates, exceeding 70 L/min have not been investigated. Therefore, the aim of this trial is therefore to study the rate of accumulation of carbon dioxide during THRIVE at two different flow rates: 40 and 100 L/min.

Condition or Disease Intervention/Treatment Phase
  • Other: THRIVE
N/A

Detailed Description

Eligible participants with signed informed consent presenting for elective surgery will have standard monitoring with ECG, pulse oximetry, blood pressure, train-of-four monitoring and capnography applied at arrival to the operating room. In addition, a circumferential electric impedance tomography thoracic elastic band with equally spaced electrodes will be placed in the 4th to 6th intercostal space. After induction of general anesthesia with a target controlled infusion of Propofol+Remifentanil and muscle relaxation with Rocuronium bromide, adequate face mask ventilation will be confirmed and arterial cannulation will be performed.

Patients will thereafter receive THRIVE at two flow rates for 10 minutes each in a randomized order. During THRIVE, video laryngoscopy will be performed with a grade 2B visualization of the larynx to establish similar airway patency during the interventions.

Before each flow, an end-tidal oxygen value of >0.85 and end-tidal carbon dioxide value of 4.5-5.0 kPa is achieved by controlled pressure regulated volume control ventilation to establish similar arterial partial pressure of oxygen and carbon dioxide at baseline. An arterial blood gas will also be analyzed before the start of each flow rate to ensure that the initial pCO2 is less than 6.0 kPa. Furthermore, a standardized lung recruitment maneuver will be performed to establish similar baseline compliance of the respiratory system.

Termination criteria will be:
  • All flow rates have been applied.

  • Severe acidemia (pH<7.10), hypercapnia (pCO2>11.0) or desaturation to SpO2 less than 90% for more than 10 seconds. These termination criteria will apply only to the current flow rate being tested. The participant will be mask ventilated until baseline parameters are established and the next THRIVE flow rate according to randomization will be applied.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
18 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
After induction of general anesthesia, confirmation of adequate face mask ventilation, and successful arterial cannulation, participants will be assigned to THRIVE flow rates in a randomized order.After induction of general anesthesia, confirmation of adequate face mask ventilation, and successful arterial cannulation, participants will be assigned to THRIVE flow rates in a randomized order.
Masking:
Single (Participant)
Masking Description:
The participants are aware of the intervention used, but not aware of the order of flow rate tests.
Primary Purpose:
Treatment
Official Title:
Flow Rate Impact on Arterial Carbon Dioxide Accumulation During Transnasal Humidified Rapid-insufflation Ventilation Exchange: a Randomized Cross-over Study
Anticipated Study Start Date :
Apr 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: THRIVE 40 L/min

40 L/min with 100% oxygen for 10 minutes.

Other: THRIVE
During general anesthesia, apneic oxygenation with a high flow nasal oxygen system is applied for 10 minutes. Video laryngoscopy will be performed to achieve similar airway patency.

Experimental: THRIVE 100 L/min

100 L/min with 100% oxygen for 10 minutes.

Other: THRIVE
During general anesthesia, apneic oxygenation with a high flow nasal oxygen system is applied for 10 minutes. Video laryngoscopy will be performed to achieve similar airway patency.

Outcome Measures

Primary Outcome Measures

  1. Arterial partial pressure of carbon dioxide (PaCO2) accumulation rate [10 minutes]

    Linear mean accumulation rate of PaCO2 during THRIVE (kPa/min)

Secondary Outcome Measures

  1. Arterial partial pressure of oxygen (PaO2) [10 minutes]

    Change of PaO2

  2. Peripheral saturation (SpO2) [10 minutes]

    Change of SpO2 and lowest SpO2

  3. End-tidal carbon dioxide fraction (EtCO2) [10 minutes]

    Change of EtCO2

  4. End-tidal oxygen fraction. (EtO2) [10 minutes]

    Change of EtO2

  5. End-expiratory lung impedance (EELI) [10 minutes]

    Change of EELI measured with electric impedance tomography

  6. Respiratory compliance [10 minutes]

    Change of dynamic and static respiratory compliance

  7. Heart rate [10 minutes]

    Change of heart rate

  8. Blood pressure [10 minutes]

    Change of systolic, diastolic and mean arterial blood pressure.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients presenting for elective surgery
Exclusion Criteria:
  • Age <18 or >65 years

  • Body Mass Index (BMI) >35 kg m-2

  • American Society of Anesthesiology classification > 2

  • Physical activity level less than 5 metabolic equivalents

  • Obstruction of the upper airways

  • Known or high clinical suspicion of difficult airway

  • Obstructive sleep apnea syndrome

  • Increased risk of aspiration

  • Pulmonary or cardiac condition resulting in a reduction of physical activity level equivalent to the New York Heart Association class of 2 or higher.

  • Any contraindication to high-flow nasal oxygen therapy or hypercapnia

  • Pregnancy or breastfeeding

  • Allergy to any of the anesthetic agents used in the study

  • Inability to comprehend oral or written information.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Uppsala University Hospital Uppsala Uppsala County Sweden 75185

Sponsors and Collaborators

  • Uppsala University Hospital

Investigators

  • Principal Investigator: Peter Frykholm, MD, PhD, Uppsala University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peter Frykholm, Consultant and Senior Lecturer, Section of Paediatric Anaesthesia and Intensive Care, Uppsala University Hospital
ClinicalTrials.gov Identifier:
NCT05234424
Other Study ID Numbers:
  • Frykholm2201
First Posted:
Feb 10, 2022
Last Update Posted:
Mar 10, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Peter Frykholm, Consultant and Senior Lecturer, Section of Paediatric Anaesthesia and Intensive Care, Uppsala University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 10, 2022